Trade Name (Agent): Epclusa (sofosbuvir and velpatasvir)
Sponsor: Gilead Sciences Inc.
Date of BT Designation Disclosure: 10/28/2015
Approval Date: 6/28/2016
Indication: Adult patients with chronic hepatitis C virus (HCV) genotypes 1,2,3,4,5, or 6 infection: -without cirrhosis or with compensated cirrhosis -with decompensated cirrhosis for use in combination with ribavirin
Category: Infectious Disease